OrthoPediatrics partners with MY01 to advance pediatric trauma care

WARSAW, Ind. - OrthoPediatrics Corp. (NASDAQ:KIDS), a $517 million market cap company showing impressive revenue growth of 26% over the last twelve months, announced Friday a new distribution partnership with medical technology company MY01 to expand access to continuous perfusion monitoring technology for pediatric trauma patients.

The collaboration will focus on improving diagnosis of acute compartment syndrome in children and adolescents through MY01’s Continuous Perfusion Sensing Technology Platform. Acute compartment syndrome is a time-sensitive emergency condition that disproportionately affects children with certain fractures and orthopedic injuries. According to InvestingPro data, OrthoPediatrics maintains a strong financial position with liquid assets exceeding short-term obligations and operates with a moderate debt level, enabling strategic partnerships like this one.

According to the companies, diagnosing this condition in pediatric patients presents unique challenges as children may struggle to verbalize pain symptoms and early warning signs can be subtle.

"Children represent the group most at-risk for compartment syndrome," said Andrew Morris, Chief Commercial Officer at MY01, in the press release.

The partnership combines MY01’s monitoring technology with OrthoPediatrics’ pediatric-focused sales force and medical education resources. This integration aims to provide clinicians with both tools and training to address compartment syndrome cases in young patients.

Fady Rayes, Vice-President of Product Development at OrthoPediatrics, stated that the partnership "extends that mission into trauma monitoring, pairing innovative technology with our focus on education and surgeon support."

OrthoPediatrics, founded in 2006, focuses exclusively on pediatric orthopedics and currently markets over 80 products serving three major categories within the pediatric orthopedic market. The company distributes its products in the United States and more than 70 countries globally, maintaining an impressive gross profit margin of 71.5%. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers this and 1,400+ other US stocks.

Montreal-based MY01, founded in 2019, develops technology that translates biological signs into real-time data to support clinical decision-making in trauma cases.

The information in this article is based on a company press release.

In other recent news, OrthoPediatrics Corporation reported its second-quarter 2025 financial results, highlighting a notable earnings per share (EPS) beat. The company achieved an EPS of -$0.11, significantly surpassing the forecasted -$0.29. Quarterly revenue was $61.1 million, marking a 16% increase year-over-year, although it fell short of the consensus estimate of $62.5 million. The company’s Trauma & Deformity sales reached $41.7 million, up 10.3% from the previous year, while Scoliosis sales saw a substantial increase to $18.5 million, up 35.4%. However, Sports Medicine/Other sales decreased to $0.9 million, down 32.9%. Analyst firms Citizens JMP and BTIG adjusted their price targets for OrthoPediatrics to $35 and $39, respectively, following the mixed financial results. Citizens JMP maintained a Market Outperform rating, while BTIG kept a Buy rating. Additionally, OrthoPediatrics announced the appointment of Kelly Fischer to its Board of Directors, succeeding Terry Schlotterback, who retired after over 15 years of service.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.